trending Market Intelligence /marketintelligence/en/news-insights/trending/MwbPkZgsITR0qBdN1gYltA2 content esgSubNav
In This List

Loxo Oncology starts rolling submission of FDA application for cancer drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Loxo Oncology starts rolling submission of FDA application for cancer drug

Loxo Oncology Inc. initiated the submission of a rolling new drug application to the U.S. Food and Drug Administration for its cancer treatment larotrectinib.

Larotrectinib is intended for treating unresectable or metastatic solid tumors with NTRK-fusion proteins in patients who require systemic therapy and have either progressed following prior treatment or have no acceptable alternative treatments.

The company expects to complete the submission in early 2018.